TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06748508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
Description: Patients were randomized in a 1:1:1 ratio to three treatment groups: control group A: pembrolizumab combined with XELOX regimen, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles. Group B: treatment regimen was pembrolizumab combined with Nab-POF regimen, the regimen was repeated every 2 weeks, and tumor efficacy was evaluated every 3 treatment cycles. Group C: treatment regimen was pembrolizumab combined with XELOX regimen and lenvatinib, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
Description: Patients were randomized in a 1:1:1 ratio to three treatment groups: control group A: pembrolizumab combined with XELOX regimen, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles. Group B: treatment regimen was pembrolizumab combined with Nab-POF regimen, the regimen was repeated every 2 weeks, and tumor efficacy was evaluated every 3 treatment cycles. Group C: treatment regimen was pembrolizumab combined with XELOX regimen and lenvatinib, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
Description: Patients were randomized in a 1:1:1 ratio to three treatment groups: control group A: pembrolizumab combined with XELOX regimen, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles. Group B: treatment regimen was pembrolizumab combined with Nab-POF regimen, the regimen was repeated every 2 weeks, and tumor efficacy was evaluated every 3 treatment cycles. Group C: treatment regimen was pembrolizumab combined with XELOX regimen and lenvatinib, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles.
Study: NCT05994248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marlex
Description: Use of non-absorbable mesh in umbilical hernia repair
Study: NCT05875506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone gel
Description: (Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone gel
Description: (Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline hyclate saturated chitosan dressing
Description: doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline hyclate saturated chitosan dressing
Description: doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
Study: NCT06750133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
Description: Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells(6-10×10\^7 CNK+ cells/kg). The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study.
Study: NCT06750965

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum M protein screening
Description: Using highly sensitivity test to screen serum M protein of all participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum M protein screening
Description: Using highly sensitivity test to screen serum M protein of all participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum M protein screening
Description: Using highly sensitivity test to screen serum M protein of all participants.
Study: NCT05904535

Intervention type: OTHER
Intervention: Cerbrospinal fluid sampling.
Description: Routine sampling of cerebrospinal fluid from the proximal external ventricular drain port.
Study: NCT06750757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate
Description: 145cc of BMAC/PRP/PPP injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Description: Both groups will undergo a hip arthroscopy to treat their condition. However, the control group will not receive a BMAC injection during the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip arthroscopy
Description: Both groups will undergo a hip arthroscopy to treat their condition. However, the control group will not receive a BMAC injection during the surgery.
Study: NCT06748898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS-WAA
Description: Before anesthesia induction, two paired of electrode pads will be placed on the upper area 1 and 2 with the skin of the treatment area exposed, and the upper and lower juxtaposition method will be adopted. The electrodes were placed close to the skin and connected with TENStem eco basic (Wuxi Jiajian Medical Device Co., Ltd.). Upper area 2 is at the middle of the palmar side of the forearm, between the palmaris longus and flexor carpi radialis.Upper area 1 is between the ulnar border on the little finger side and the flexor carpi ulnaris tendon.Stimulation parameters of TENS-WAA are alternating dense-disperse wave with a frequency of 2Hz and a pulse width of 200μs, and a frequency of 100Hz with a pulse width of 150μs, alternating every 3 seconds ，intensity required to reachthe maximum tolerable level without causing pain, continuous stimulation until the end of surgery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non TENS-WAA
Description: Before anesthesia induction, two paired of electrode pads will be placed on the same position without current stimulation.
Study: NCT06748716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-blocking glasses
Description: The investigators hypothesize that blue-blocking glasses (intervention) is more effective than placebo.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Clear glasses
Description: Clear-lensed glasses are placebo
Study: NCT06751407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single level SPSIPB
Description: The procedure will be performed with the patient in the prone position in the preoperative period. After the scapula is slightly shifted laterally, the US probe is held sagittally at the upper corner of the scapula spine, and the 3rd rib and the serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and entered between the serratus posterior superior and the 3rd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-level SPSIPB
Description: In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 2nd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 10 ml of 0.25% bupivacaine will be used. Then, the US probe will be held sagittally in the medial part of the scapula spine, and the 4th rib and serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 4th rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block site is confirmed, 10 ml of 0.25% bupivacaine will be used. A total of 20 ml of 0.25% bupivacaine will be used.
Study: NCT06748417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute Cognitive Training
Description: Participants will receive the intervention in person once within in the study for 30 minutes. During the intervention, participants will receive a cognitive training session consisting of an upper extremity, lower extremity, and whole-body reaction time task. The device (5 LED) will be placed in front of participants in all tasks, and participants will be asked to deactivate lights that illuminate for a period of 30 seconds with 30 seconds of rest. For the upper and lower extremity tasks, these will be repeated on both limbs. The purpose of the tasks are to pre-train reaction time in an isolated fashion, requiring participants to use either hands or feet to deactivate the lights, as well as incorporate whole-body movement in the third task along with a decision-making (color-matching) component.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute Cognitive Training
Description: Participants will receive the intervention in person once within in the study for 30 minutes. During the intervention, participants will receive a cognitive training session consisting of an upper extremity, lower extremity, and whole-body reaction time task. The device (5 LED) will be placed in front of participants in all tasks, and participants will be asked to deactivate lights that illuminate for a period of 30 seconds with 30 seconds of rest. For the upper and lower extremity tasks, these will be repeated on both limbs. The purpose of the tasks are to pre-train reaction time in an isolated fashion, requiring participants to use either hands or feet to deactivate the lights, as well as incorporate whole-body movement in the third task along with a decision-making (color-matching) component.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-stimulating Rest
Description: Participants will receive the intervention in person once within the study for 30 minutes. During the intervention, participants will watch, while seated, a 30-minute segment of a nature documentary. The purpose of this intervention is to ensure no additional cognitive or movement training that would improve performance on the dual-task test occurs during the intended rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-stimulating Rest
Description: Participants will receive the intervention in person once within the study for 30 minutes. During the intervention, participants will watch, while seated, a 30-minute segment of a nature documentary. The purpose of this intervention is to ensure no additional cognitive or movement training that would improve performance on the dual-task test occurs during the intended rest period.
Study: NCT06748703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Treatment
Description: CPAP therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
Study: NCT06749509

Intervention type: OTHER
Intervention: Face-to-face musculoskeletal rehabilitation
Description: Kela's rehabilitation course for those with MSD includes two 5-day periods and one 3-day period of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation center over a 9-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation course is group-based and provided free of charge. The 9-month rehabilitation period also includes calls to the participants before and after rehabilitation. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A medical statement is required when applying for the rehabilitation course.

Intervention type: OTHER
Intervention: Musculoskeletal telerehabilitation
Description: Kela´s MSD telerehabilitation course is arranged entirely as telerehabilitation, and it includes videoconferencing, online rehabilitation, and group-based rehabilitation days implemented by a multidisciplinary team of rehabilitation experts. Participation does not require particular IT skills, but appropriate equipment (e.g., mobile phone, laptop, tablet computer) is needed. The rehabilitation course is free of charge, and the total duration, including the calls before and after rehabilitation, is approximately 7 months. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A physiotherapist's recommendation is required when applying for the telerehabilitation course

Intervention type: OTHER
Intervention: Controls
Description: The control participants have an MSD diagnosis and musculoskeletal symptoms. Based on an occupational physiotherapist's brief evaluation they are eligible to apply for Kela's musculoskeletal rehabilitation (the interventions below). By them own choice, however, they will not participate in these rehabilitation programs in the near future. The controls are recruited via two occupational health care producers in the private sector.
Study: NCT06748976

Intervention type: OTHER
Intervention: Positive sham neurofeedback
Description: Participants receive simulated positive reinforcement feedback designed to mimic successful modulation of EEG alpha rhythms, despite the feedback not being directly based on their actual neural activity. This condition aims to create the perception of improved attentional control.
Study: NCT06021054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veligrotug (VRDN-001)
Description: Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 IV infusions of placebo
Study: NCT04461210

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermographic Imaging and Mechanical Pain Assessment
Description: Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermographic Imaging and Mechanical Pain Assessment
Description: Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera
Study: NCT06496997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone at a dose of 1 mg/kg/day (an average dose of 70 mg/day based on 70 kg body weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone at an equivalent dose of 13 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone at an equivalent dose of 350 mg/day
Study: NCT06276946

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard radiotherapy
Description: radiotherapy planning goal is to restrict the mean parotid dose is equal to or less than 14Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: experimental radiotherapy
Description: radiotherapy planning goal is to restrict the parotid duct dose is equal to or less than 14Gy
Study: NCT04569435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: IV Infusion
Study: NCT06748976

Intervention type: OTHER
Intervention: Negative sham neurofeedback
Description: Participants receive simulated negative reinforcement feedback that mimics unsuccessful modulation of EEG alpha rhythms, regardless of their actual neural activity. This condition is intended to simulate reduced attentional control.

Intervention type: OTHER
Intervention: Control
Description: Participants perform the same attentional task but without receiving any feedback. This condition serves as a baseline to evaluate the effects of the sham neurofeedback interventions on EEG alpha rhythm modulation.
Study: NCT06751251

Intervention type: DIAGNOSTIC_TEST
Intervention: IHC: Immunohistochemistry
Description: Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.

Intervention type: DIAGNOSTIC_TEST
Intervention: IHC: Immunohistochemistry
Description: Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.

Intervention type: GENETIC
Intervention: RNA-seq
Description: RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.

Intervention type: GENETIC
Intervention: RNA-seq
Description: RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.
Study: NCT05634005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: In blood product order entry within the electronic health record, the ordering provider is required to select an indication for the blood product order. If the patient's laboratory values are not in line with the guideline indication selected, a clinical decision support alert will fire and be shown to the ordering provider. This alert will inform the provider that the order is outside institutional guidelines and the provider has the option to cancel the order (or bypass the order and select a reason for proceeding with the order).
Study: NCT04925427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management and Peer Recovery
Description: A blend between a Critical Time Intervention (CTI) case management model and a peer recovery coaching approach. CORI will employ peer-based case management/recovery coaching and other transitional services (e.g., peer navigation) to provide support and service linkages to medication-assisted treatment (MAT) and harm reduction interventions to reduce subsequent opioid use and related harms.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Naloxone-Only
Description: Participants will be trained on naloxone administration, and upon re-entry, they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
Study: NCT05121896

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Scan
Description: 7.0 tesla functional MRI scan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Scan
Description: 7.0 tesla functional MRI scan
Study: NCT05746793

Intervention type: PROCEDURE
Intervention: endometrium biopsy
Description: The procedure is performed without any anesthesia and takes approximately 5 minutes.~A small plastic pipelle is put through the cervix into the uterine cavity. The endometrial tissue is aspirated into the pipelle.

Intervention type: PROCEDURE
Intervention: endometrium biopsy
Description: The procedure is performed without any anesthesia and takes approximately 5 minutes.~A small plastic pipelle is put through the cervix into the uterine cavity. The endometrial tissue is aspirated into the pipelle.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transabdominal ultrasound
Description: Evaluation of fetal biometry and doppler flow study using ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transabdominal ultrasound
Description: Evaluation of fetal biometry and doppler flow study using ultrasound.
Study: NCT03889834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Blood Transfusion
Description: Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Blood Transfusion
Description: Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days

Intervention type: OTHER
Group type: OTHER
Intervention: No transfusion
Description: no transfusion
Study: NCT05447806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support
Description: This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
Study: NCT03998319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase (1/3 systemic weight based dose)
Description: 50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water for injection (WFI)
Description: Placebo comparative arm.
Study: NCT06111235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cretostimogene Grenadenorepvec
Description: Engineered Oncolytic Adenovirus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: n-dodecyl-B-D-maltoside
Description: Transduction-enhancing agent
Study: NCT06221969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide will be administered subcutaneously.
Study: NCT04973098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT0181 Cells
Description: 5 dose levels each with or without lymphocyte clearance were tentatively determined.
Study: NCT05746793

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral phlebotomy
Description: single puncture collection of peripheral venous blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral phlebotomy
Description: single puncture collection of peripheral venous blood.